HomeAbout Publications Awards and Funding Contact



(Google scholar citations)

  1. Hackseq Organizing Committee 2016: Babaian A, Drögemöller B, Grande B, Jackman S, Lee A, Lin S, Loucks C, Suarez-Gonzalez A, Timbers T, Wright G (2017) hackseq: Catalyzing collaboration between biological and computational scientists via hackathon. F1000Res 6 DOI: 10.12688/f1000research.10964.1.
  2. Drögemöller B, Monzon J, Bhavsar A, Borrie A, Brooks B, Wright G, Liu G, Fadhel E, Renouf D, Kollmannsberger C, Bedard P, Aminkeng F, Amstutz U, Hildebrand C, Gunaretnam E, Critchley C, Chen Z, Brunham L, Hayden M, Ross C, Gelmon K, Carleton B (2017) SLC16A5 genetic variation confers protection from cisplatin-induced ototoxicity in adult testicular cancer patients. JAMA Oncol DOI: 10.1001/jamaoncol.2017.0502.
  3. Kay C, Tirado-Hurtado I, Cornejo-Olivas M, Collins J, Wright G, Inca-Martinez M, Veliz-Otani D, Ketelaar M, Slama R, Ross C, Mazzetti P, Hayden M (2016) The Major Targetable Huntington Disease Haplotype in Latin America has Distinct Amerindian and European Origins. Eur J Hum Genet DOI: 10.1038/ejhg.2016.169.
  4. Wright G, Carleton B, Hayden M, Ross C (2016) The global spectrum of protein-coding pharmacogenomic diversity. Pharmacogenomics J DOI:10.1038/tpj.2016.77.
  5. Wang Z, Sadovnick A, Traboulsee A, Ross J, Bernales C, Encarnacion M, Yee I, de Lemos M, Greenwood T, Lee J, Wright G, Ross C, Zhang S, Song W, Vilariño-Güell C (2016) Case-Control Studies Are Not Familial Studies. Neuron 92, 339-34.
  6. Wang Z, Sadovnick A, Traboulsee A, Ross J, Bernales C, Encarnacion M, Yee I, de Lemos M, Greenwood T, Lee J, Wright G, Ross C, Zhang S, Song W, Vilariño-Güell C (2016) Nuclear receptor NR1H3 in familial multiple sclerosis. Neuron 90, 948-54.
  7. Drögemöller B, Emsley R, Chiliza B, van der Merwe L, Wright G, Daya M, Hoal E, Malhotra A, Lencz T, Zhang J, Asmal L, Niehaus D, Warnich L (2016) The identification of novel genetic variants associated with antipsychotic treatment response outcomes in first episode schizophrenia patients. Pharmacogenet Genomics 26, 235-42.
  8. Röhrich C, Drögemöller B, Ikediobi I, van der Merwe L, Grobbelaar N, Wright G, Warnich L (2016) CYP2B6*6 and CYP2B6*18 predict long-term efavirenz exposure measured in hair samples in HIV-positive South African women. AIDS Res Hum Retroviruses 32, 529-38.
  9. Dodgen T, Drögemöller B, Wright G, Warnich L, Steffens F, Cromarty A, Alessandrini M, Pepper M (2015) Evaluation of predictive CYP2C19 genotyping assays relative to measured phenotype in a South African population. Pharmacogenomics 16, 1343-54.
  10. Wright G, Adeyemo A, Tiffin N (2014) Informed Consent and ethical re-use of African genomic data. Hum Genomics 8:18.
  11. Bosch J, Noubiap J, Dandara C, Makubalo N, Wright G, Domelevo Entfellner J, Tiffin N, Wonkam A (2014) Sequencing of GJB2 in Cameroonians and Black South Africans and comparison to 1000 Genomes Project data support the need to revise the strategy for discovery of non-syndromic deafness genes in Africans. OMICS 18: 705-10.
  12. Drögemöller B, Wright G, Warnich L (2014) Considerations for rare variants in drug metabolism genes and the clinical implications. Expert Opin Drug Metab Toxicol 10, 873-84.
  13. Drogemöller B, Niehaus D, Chiliza B, van der Merwe L, Asmal L, Malhotra A, Wright G, Emsley R, Warnich L (2014) Patterns of variation influencing antipsychotic treatment outcomes in South African first-episode schizophrenia patients. Pharmacogenomics 15, 189-99.
  14. Drögemöller B, Wright G, Niehaus D, Emsley R, Warnich L (2013) Next generation sequencing of pharmacogenes: a critical analysis focussing on schizophrenia treatment. Pharmacogenet Genomics 23, 666-674.
  15. Wright G, Koornhof P, Adeyemo A, Tiffin N (2013) Ethical and legal implications of whole genome and whole exome sequencing in African populations. BMC Med Ethics 14, 21.
  16. Drögemöller B, Plummer M, Korkie L, Agenbag G, Dunaiski A, Niehaus D, Koen L, Gebhardt S, Hillermann R, van den Berg N, Olckers A, Wright G, Warnich L (2013) Characterisation of the genetic variation present in CYP3A4 in three South African populations. Front Gene 4, 17.
  17. Dodgen T, Hochfeld W, Fickl H, Asfaha S, Durandt C, Rheeder P, Drögemöller B, Wright G, Warnich L, Labuschagne C, van Schalkwyk A, Gaedigk A, Pepper M (2013) Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study. BMC Med Genet 14, 20.
  18. Wright G, Niehaus D, van der Merwe L, Koen L, Kinnear C, Drögemöller B, Warnich L (2012) Association of MB-COMT polymorphisms with schizophrenia-susceptibility and symptom severity in an African cohort. Prog Neuropsychopharmacol Biol Psychiatry 39, 163-9.
  19. Özdemir V, Fisher E, Dove E, Burton H, Wright G, Zimmermn R, Masellis M, Warnich L (2012) End of the beginning and public health pharmacogenomics: knowledge in ‘Mode 2’ and P5 medicine. Curr Pharmacogenomics Person Med 10, 1-6.
  20. Koen L, Niehaus D, Wright G, Warnich L, de Jongh G, Emsley R, Mall S (2012) Chromosome 22q11 in a Xhosa schizophrenia population. S Afr Med J, 102, 165-6.
  21. Drögemöller B, Wright G, Niehaus D, Emsley R, Warnich L (2011) Whole genome resequencing in pharmacogenomics: moving away from past disparities to globally representative applications. Pharmacogenomics 12, 1717-28.
  22. Wright G, Niehaus D, Koen L, Drögemöller B, Warnich L (2011) Psychiatric genetics in South Africa: cutting a rough diamond. Afr J Psychiatry (Johannesbg) 14, 355-66.
  23. Warnich L, Drögemöller B, Pepper M, Dandara C, Wright G (2011) Pharmacogenomic research in South Africa: lessons learned and future opportunities in the Rainbow Nation. Curr Pharmacogenomics Person Med 9, 191-207.
  24. Drögemöller B, Wright G, Niehaus D, Koen L, Malan S, Da Silva D, Hillermann-Rebello R, La Grange A,  Venter M, Warnich L (2010) Characterization of the genetic profileof CYP2C19 in two South African populations. Pharmacogenomics 11, 1095–103.
  25. Wright G, Niehaus D, Drögemöller B, Koen L, Gaedigk A, Warnich L (2010) Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population. Ann Hum Genet 74, 340–50.